Hector R. Wong, MD

My Biography & Research My Education My Publications

Visit the Wong Lab

Director, Division of Critical Care Medicine

Professor, UC Department of Pediatrics

hector.wong@cchmc.org

513-636-4259

513-636-4267

Board Certified

My Biography & Research

Additional Languages

Spanish

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Pediatric Intensive Care Unit PICU, Critical Care

My Education

MD: University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ, 1989.

Residency: Department of Pediatrics, George Washington University School of Medicine, Children's National Medical Center, Washington, DC, 1990 to 1992.

Fellowship: Clinical Fellow, Department of Anesthesiology, Division of Pediatric Critical Care Medicine, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, PA, 1992 to 1995; Research Fellow, Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 1992 to 1995.

Certification: National Board of Medical Examiners, 1990; Diplomate, American Board of Pediatrics, 1993; American Board of Pediatrics: Sub-Board of Pediatric Critical Care Medicine, 1996.

My Publications

Precision medicine in pediatric sepsis. Atreya, MR; Wong, HR. Current Opinion in Pediatrics. 2019; 31:322-327.

PPARα contributes to protection against metabolic and inflammatory derangements associated with acute kidney injury in experimental sepsis. Iwaki, T; Bennion, BG; Stenson, EK; Lynn, JC; Otinga, C; Djukovic, D; Raftery, D; Fei, L; Wong, HR; Liles, WC; et al. Physiological Reports. 2019; 7.

HDL Cholesterol: A "Pathogen Lipid Sink " for Sepsis?. Jones, TK; Wong, HR; Meyer, NJ. American Journal of Respiratory and Critical Care Medicine. 2019; 199:812-814.

Evidence of endotypes in pediatric acute hypoxemic respiratory failure caused by sepsis. Yehya, N; Thomas, NJ; Wong, HR. Pediatric Critical Care Medicine. 2019; 20:110-112.

The Pediatric Sepsis Biomarker Risk Model (PERSEVERE) Biomarkers Predict Clinical Deterioration and Mortality in Immunocompromised Children Evaluated for Infection. Jacobs, L; Berrens, Z; Stenson, EK; Zackoff, MW; Danziger, LA; Lahni, P; Wong, HR. Scientific Reports. 2019; 9.

Olfactomedin 4 marks a subset of neutrophils in mice. Alder, MN; Mallela, J; Opoka, AM; Lahni, P; Hildeman, DA; Wong, HR. Innate Immunity. 2019; 25:22-33.

A community approach to mortality prediction in sepsis via gene expression analysis. Sweeney, TE; Perumal, TM; Henao, R; Nichols, M; Howrylak, JA; Choi, AM; Bermejo-Martin, JF; Almansa, R; Tamayo, E; Davenport, EE; et al. Nature Communications. 2018; 9.

Interleukin-27 as a candidate diagnostic biomarker for bacterial infection in immunocompromised pediatric patients. Jacobs, L; Berrens, Z; Stenson, EK; Zackoff, M; Danziger-Isakov, L; Lahni, P; Wong, HR. PLoS ONE. 2018; 13.

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. Kaplan, JM; Zingarelli, B; Krallman, K; Girdwood, ST; Lagory, D; Mizuno, T; Fei, L; Wong, HR; Vinks, AA. Intensive Care Medicine. 2018; 44:2006-2008.

Hyperchloremia is associated with acute kidney injury in pediatric patients with septic shock. Stenson, EK; Cvijanovich, NZ; Allen, GL; Thomas, NJ; Bigham, MT; Weiss, SL; Fitzgerald, JC; Jain, PN; Meyer, K; Quasney, M; et al. Intensive Care Medicine. 2018; 44:2004-2005.